• Bone Health
  • Immunology
  • Hematology
  • Respiratory
  • Dermatology
  • Diabetes
  • Gastroenterology
  • Neurology
  • Oncology
  • Ophthalmology
  • Rare Disease
  • Rheumatology

The Top 5 Biosimilar Articles for the Week of August 23

Video

Here are the top 5 biosimilar articles for the week of August 23, 2021.

Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilar articles for the week of August 23, 2021.

Number 5: UnitedHealthcare (UHC) has changed its policy to indicate that the bevacizumab biosimilars Mvasi and Zirabev will not be covered in the treatment of certain ophthalmic conditions or considered ophthalmically equivalent to Avastin, the reference product.

Number 4: Rumors that HHS could calculate payment for biosimilars differently under a potential policy change have sparked concerns among providers and biosimilar developers. If the rumors are correct, the Medicare Part B payment methodology for biosimilars would be overhauled for the second time in 4 years.

Number 3: How many switches between a biosimilar and reference product will be sufficient to demonstrate that the risk of transitioning is minimal? A virtual study verified the strength of FDA guidance.

Number 2: A multicenter study of recombinant human growth hormone (rhGH) in children with Turner syndrome demonstrated safety and efficacy comparable to the reference product.

Number 1: Use of the 351(k) biosimilar approval pathway entails legal challenges, high costs, and potentially higher clinical evidence standards. Sarfaraz K. Niazi, PhD, suggested that using the 351(a) pathway for standalone drugs and copy products may be faster and better in part 3 of a series.

To read all of these articles and more, visit centerforbiosimilars.com.

Recent Videos
 Here are the top 5 biosimilar articles for the week of July 15, 2024.
Jeffrey Casberg, MS, RPh
Here are the top 5 biosimilar articles for the week of July 8, 2024.
Here are the top 5 biosimilar articles for the week of July 1, 2024.
Jeffrey Casberg, RPh, MS.
Here are the top 5 biosimilar articles for the week of June 24, 2024.
Jeffrey Casbery, IPD Analytics
Here are the top 5 biosimilar articles for the week of June 17, 2024.
Here are the top 5 biosimilar articles for the week of June 10, 2024.
Lakesha Farmer, PharmD
Related Content
© 2024 MJH Life Sciences

All rights reserved.